HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) announced significant progress in its mission to provide broader access to advanced dermatologic care. Recent updates by the American Medical Association (AMA) to CPT codes 96920-96922 will now expand reimbursement coverage for excimer laser treatments to include a wide range of inflammatory and autoimmune skin conditions in addition to psoriasis.
The updated codes address more than two decades of clinical evidence supporting STRATA’s XTRAC® Excimer Laser System as an effective, non-drug option for chronic skin diseases. Conditions such as vitiligo, atopic dermatitis, lichen planus, alopecia areata, cutaneous T-cell lymphoma (CTCL), and mycosis fungoides are now explicitly included, significantly improving access for millions of potential patients.
“This CPT update not only establishes the use of excimer laser beyond psoriasis, but it validates volumes of data demonstrating the utility,” said Dr. Dolev Rafaeli, CEO of STRATA. “It supports our mission to expand access to safe, effective, non-drug dermatologic solutions for patients in need.”
Broadening Patient Access
The expanded reimbursement is expected to reduce systemic denials and eliminate the need for prior authorizations, which have historically created hurdles for non-psoriasis treatments. STRATA estimates the coverage expansion could grow the addressable patient base from 10 million psoriasis patients to over 30 million, including 3 million with vitiligo, 16.5 million with atopic dermatitis, and 4.6 million with alopecia areata.
“Phototherapy—and excimer lasers in particular—have transformed the treatment landscape for vitiligo and atopic dermatitis,” said Dr. Mark Lebwohl, Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai. “This CPT code update strongly validates 308nm excimer laser’s broader clinical value and represents a vital step toward expanding patient access.”
Commercial and Clinical Impact
STRATA projects the enhanced coverage will drive significant commercial growth. Currently, non-psoriasis indications represent 30% of XTRAC treatment volumes but require additional payer pre-authorizations, which limit utilization. The updated codes remove these barriers, positioning the platform for broader adoption. STRATA expects this access to accelerate revenue growth, particularly under its recurring-use business model, which includes over 1,400 clinics and 4,000 medical providers in the U.S.
“The expanded access to therapy could increase use dramatically,” added Dr. Rafaeli. “This is the inflection point we’ve worked toward for decades, reinforcing our commitment to making advanced phototherapy accessible and effective across a wide range of conditions.”
This milestone marks a pivotal moment for STRATA, its providers, and the millions of patients seeking safe, non-invasive treatment options for chronic skin conditions. With the groundwork laid for further growth, the company continues to shape the future of dermatologic care.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.